AI Terminal
ABIVAX
AGM Information • Nov 15, 2022
1063_rns_2022-11-15_263f5abc-f537-4f4a-8b46-8419a787fc87.html
AGM Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 15 November 2022 18:00
Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting
EQS-News: ABIVAX / Key word(s): AGM/EGM
Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting
15.11.2022 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
ABIVAX RELEASES THE RESULTS OF ITS NOVEMBER 9, 2022 AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING
- Shareholders approved all proposed resolutions
PARIS, France, November 15, 2022 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held an ad hoc ordinary and extraordinary general meeting of shareholders on November 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of Directors.
The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, delegations granted to the Board of Directors related to financial transactions and incentive mechanisms for the benefit of the Company’s employees, managers and/or other partners.
Details on the vote results will be available on the company’s website.
*****
About Abivax (www.abivax.com)
Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France Primatice Thomas Roborel de Climens [email protected] +33 6 78 12 97 95 |
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858 |
15.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com